UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

~~x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15~~(dMark One) ~~OF THE SECURITES EXCHANGE ACT OF 1934~~

~~For~~☒ QUARTERLY REPORT ~~the~~UNDER ~~quarter~~SECTION ~~period~~13 ~~ended:~~OR ~~March~~15(d) ~~31,~~OF ~~2016~~THE SECURITIES EXCHANGE ACT OF 1934

¨For the ~~TRANSITION~~quarterly ~~REPORT~~period ~~PURSUANT~~ended TOAugust ~~SECTION~~31, ~~13 OR 15 (d) OF THE EXCHANGE ACT OF 1934~~2016

~~For~~☐ TRANSITION REPORT ~~the~~UNDER ~~transition~~SECTION ~~period~~13 ~~form _______~~OR to15(d) ~~_______Commission~~OF ~~File~~THE ~~number~~EXCHANGE ~~000-53207~~ACT

~~PLATA~~For the ~~RESOURCES,~~transition ~~INC.~~period ~~(Exact~~from ~~name~~____________ ofto ~~registrant as specified in its charter)~~____________

Nevada		75-3267338
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

Commission file number: 000-53207

~~2911 Park Avenue~~NEXUS BIOPHARMA, ~~Pasay City, Metro Manila, Philippines~~ INC.

(Exact name of small business issuer as specified in its charter)

Nevada

75-3267338

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

8 Hillside Ave, Suite 108, Montclair, NJ 07042

(Address of principal executive offices)

~~632~~(973) 524-~~886-788~~6100

(~~Registrant's~~ Registrants telephone number, including area code)

~~N/A~~ Plata Resources, Inc., 2911 Park Avenue, Pasay City, Metro Manila, Philippines,

Former fiscal year end: December 31

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the ~~past~~preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes x ☐ No ¨

Indicate by check mark whether the registrant ishas asubmitted ~~large~~electronically ~~accelerated~~and ~~filer,~~posted anon ~~accelerated~~its ~~filer,~~corporate aWeb ~~non-accelerated~~site, ~~filer~~if any, orevery aInteractive Data ~~small~~File ~~reporting~~required ~~company.~~to ~~See~~be ~~definition~~submitted and posted pursuant to Rule 405 of ~~"large~~Regulation ~~accelerated~~S-T ~~filer",~~(§232.405 ~~"accelerated~~of ~~filer"~~this ~~and~~chapter) ~~"small~~during ~~reporting~~the preceding ~~company"~~12 ~~Rule~~months ~~12b-2~~(or offor such shorter period that the ~~Exchange~~registrant ~~Act~~was required to submit and post such files). ☒ Yes ☐ No

~~Large~~Indicate by check mark whether the registrant is a large accelerated filer, ¨an ~~Accelerated~~accelerated filer, ¨a ~~Non~~non-accelerated filer, ¨or ~~Small~~a smaller reporting company; xas ~~(Do~~defined ~~not~~within ~~check~~Rule if12b-2 aof ~~small~~the ~~reporting~~Exchange ~~company)~~Act.

~~Indicate~~☐ byLarge ~~check~~accelerated ~~mark~~filer ~~whether~~☐ ~~the~~Accelerated ~~registrant~~filer is☐ ~~a shell company (as defined in Rule 12b~~Non-2accelerated offiler ~~the~~☒ ~~Exchange~~Smaller ~~Act)~~reporting ~~Yes ¨ No x~~company

~~APPLICABLE~~Indicate by ~~ONLY~~check TOmark ~~ISSUERS~~whether ~~INVOLVED~~the INregistrant ~~BANKRUPTCY~~is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

~~PROCEEDINGS~~The ~~DURING~~number ~~THE~~of ~~PROCEDING~~shares ~~FIVE~~outstanding ~~YEARS~~of each of the issuer's classes of common equity as of October 24, 2016: 64,300,000 shares of common stock.

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 after the distribution of securities subsequent to the distribution of securities under a plan confirmed by a court. Yes ¨ No ¨Contents

APPLICABLE ONLY TO CORPORATE ISSUERS:

		Page
		Number

PART I	FINANCIAL INFORMATION

Item 1	Financial Statements	1

	Consolidated Balance Sheets as of August 31, 2016 (unaudited) and February 29, 2016	1

	Consolidated Statements of Operations for the Three and Six Months Ended August 31, 2016 and 2015 (unaudited)	2

	Consolidated Statement of Stockholder's Equity at August 31 2016 (unaudited)	3

	Consolidated Statements of Cash Flows for the Six Months Ended August 31, 2016 and 2015 (unaudited)	4

	Notes to Condensed Consolidated Unaudited Financial Statements	5

Item 2	Management's Discussion and Analysis of Financial Condition and Results of Operations	8

Item 3	Quantitative and Qualitative Disclosures About Market Risk

Item 4	Controls and Procedures	13

PART II	OTHER INFORMATION

Item 1	Legal Proceedings	14

Item 1A	Risk Factors	14

Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	14

Item 3	Defaults Upon Senior Securities	14

Item 4	Mine Safety Disclosures	14

Item 5	Other Information	14

Item 6	Exhibits	15

SIGNATURES		16

~~Indicate~~PART I ~~the~~- ~~number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:~~FINANCIAL INFORMATION

~~April~~Item 1 ~~30,~~– ~~2016:~~Financial ~~63,800,000 common shares~~Statements

		Page Number
PART I. FINANCIAL INFORMATION
ITEM 1.	Financial Statements (unaudited)		3
	Condensed Balance Sheets as at March 31, 2016 and December 31, 2015		4
	Condensed Statements of Operations For the three months ended March 31, 2016 and 2015		5
	Condensed Statements of Cash Flows For the three months ended March 31, 2016 and 2015		6
	Notes to the Condensed Financial Statements.		7
ITEM 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations		11
ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk		22
ITEM 4.	Controls and Procedures		22
PART II. OTHER INFORMATION
ITEM 1.	Legal Proceedings		24
ITEM 1A.	Risk Factors		24
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds		24
ITEM	Defaults Upon Senior Securities		24
ITEM 4.	Mine Safety Disclosure		24
ITEM 5.	Other Information		24
ITEM 6.	Exhibits		25
SIGNATURES.			26

NEXUS BIOPHARMA, INC.

Consolidated Balance Sheets

	August 31			February 29
	2016			2016
	(Unaudited)
ASSETS

CURRENT ASSETS
Cash	$	62,441		$	9,925
Total Current Assets		62,441			9,925

Intangible Asset, net		7,770			-

TOTAL ASSETS	$	70,211		$	9,925

LIABILITIES AND STOCKHOLDERS' DEFICIT

LIABILITIES

Accounts payable and accrued expenses	$	839,977		$	735,606
Stock payable		100,000			-
Note payable		292,500			-

Total Current Liabilities		1,232,477			735,606

Convertible notes payable - net of unamortized debt discount of $15,555 and 18,889		44,445			41,111

Total Long Term Liabilities		44,445			41,111

TOTAL LIABILITIES		1,276,922			776,717

STOCKHOLDERS' DEFICIT

Common stock, $.00001 par value; 100,000,000 shares authorized; 64,309,655 and 31,552,524 shares issued and outstanding, respectively		643			315
Additional paid-in-capital		1,839,991			1,841,240
Accumulated stockholders' deficit		(3,047,345	)		(2,608,347	)
Total Stockholders' Deficit		(1,206,711	)		(766,792	)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	70,211		$	9,925

The accompanying notes are an integral part of these financial statements.

NEXUS BIOPHARMA, INC.

Consolidated Statements of Operations

	Three months ended						Six months ended
	August 31, 2016			August 31, 2015			August 31, 2016			August 31, 2015
	(unaudited)			(unaudited)			(unaudited)			(unaudited)

OPERATING EXPENSES
General and administrative	$	161,403		$	761,222		$	409,417		$	803,273
Research and development		8,904			7,500			16,404			110,900

Total Operating Expenses		170,307			768,722			425,821			914,173

OTHER INCOME (EXPENSE)
Interest expense, net		(9,033	)		-			(13,177	)		-

NET LOSS	$	(179,340	)	$	(768,722	)	$	(438,998	)	$	(914,173	)

BASIS AND DILUTED NET LOSS PER SHARE	$	0.00		$	(0.29	)	$	(0.01	)	$	(0.37	)

WEIGHTED AVERAGE SHARES OUTSTANDING - BASIS AND DILUTED		61,155,309			2,606,524			47,408,459			2,452,598

The accompanying notes are an integral part of these financial statements.

~~PART I~~NEXUS BIOPHARMA, ~~– FINANCIAL STATEMENTS~~INC.

~~ITEM~~Consolidated Statement 1.of ~~FINANCIAL~~Stockholders' ~~STATEMENTS~~Deficit

~~The accompanying condensed balance sheets of Plata Resources, Inc. at March 31, 2016 (with comparative figures as at December 31, 2015) and~~ For the ~~condensed~~six ~~statements of operations and cash flows for the three~~ months ended ~~March~~August 31, 2016 and 2015 have been prepared by the Company's management in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature.

~~Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that can be expected for the year ending December 31, 2016.~~(unaudited)

							Additional						Total
	Common Stock						Paid-in			Accumulated			Stockholders'
	Shares			Amount			Capital			Deficit			Deficit
Balance at February 29, 2016		31,552,524		$	315		$	1,841,240		$	(2,608,347	)	$	(766,792	)

Issuance of common stock for services		4,457,132			45			91,755			-			91,800

Cancellation of shares		(35,500,000	)		(355	)		355						-

Adjustment due to the reverse merger		63,800,000			638			(93,359	)					(92,721	)

Net loss		-			-			-			(438,998	)		(438,998	)

Balance at August 31, 2016		64,309,656		$	643		$	1,839,991		$	(3,047,345	)	$	(1,206,711	)

~~PLATA~~The accompanying ~~RESOURCES,~~notes ~~INC~~are an integral part of these financial statements.

~~CONDENSED BALANCE SHEETS~~3

	March 31,2016			December 31,2015
	(Unaudited)
ASSETS
CURRENT ASSETS
Cash	$	-		$	-
TOTAL CURRENT ASSETS	$	-		$	-
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
CURRENT LIABILITIES
Accounts payable	$	26,997		$	25,947
Advances from related parties		65,724			59,470
TOTAL CURRENT LIABILITIES		92,721			85,417
STOCKHOLDERS' DEFICIENCY
Common stock Issued and outstanding 750,000,000 shares authorized, at $0.001 par value 63,800,000 shares issued and outstanding (December 31, 2015 – 63,800,000)		63,800			63,800
Additional paid-in capital		41,900			41,900
Accumulated deficit		(198,421	)		(191,117	)
TOTAL STOCKHOLDERS' DEFICIENCY		(92,721	)		(85,417	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	$	-		$	-

NEXUS BIOPHARMA, INC.

~~The~~Consolidated Statements ~~accompanying notes are an integral part~~ of ~~these~~Cash ~~condensed financial statements.~~Flows

	For the six months ended
	August 31, 2016			August 31, 2015
	(unaudited)			(unaudited)

CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(438,998	)	$	(914,173	)
Adjustments to reconcile net loss to net cash used by operating activities
Amortization of debt discount		3,334			-
Amortization expense		480			-
Stock based compensation		91,800			625,000
Change in operating assets and liabilities
Accounts payable and accrued expenses		11,650			267,121
NET CASH USED IN OPERATING ACTIVITIES		(331,734	)		(22,052	)

CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid for website development costs		(8,250	)		-
NET CASH USED IN INVESTING ACTIVITIES		(8,250	)		-

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes payable		292,500
Proceeds from equity line of credit		100,000			-
NET CASH PROVIDED BY FINANCING ACTIVITIES		392,500			-

NET INCREASE (DECREASE) IN CASH		52,516			(22,052	)

Cash at the beginning of the period		9,925			22,052

Cash at the end of the period	$	62,441		$	-

NON CASH TRANSACTIONS
Cancellation of shares		355			-
Adjustment due to the reverse merger		92,721			-

SUPPLEMENTAL DISCLOSURES:
Interest paid	$	-		$	-
Income taxes paid	$	-		$	-

~~PLATA~~The accompanying ~~RESOURCES,~~notes ~~INC~~are an integral part of these financial statements.

~~CONDENSED STATEMENTS OF OPERATIONS~~4

~~(Unaudited)~~NEXUS BIOPHARMA, INC.

	Three MonthsEndedMarch 31,2016			Three MonthsEndedMarch 31,2015
REVENUE	$	-		$	-
EXPENSES
General and Administrative Expenses		7,304			20,168
Total Operating Expenses		7,304			20,168
NET LOSS	$	(7,304	)	$	(20,168	)
Basic and Diluted Loss Per Common Shares	$	(0.00	)	$	(0.00	)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted		63,800,000			63,800,000

Notes to Consolidated Financial Statements

~~The~~August 31, ~~accompanying~~2016 ~~notes~~and ~~are an integral part of these condensed financial statements.~~2015

5(Unaudited)

~~PLATA~~NOTE 1 ~~RESOURCES,~~– ~~INC.~~NATURE OF OPERATIONS AND GOING CONCERN

~~CONDENSED~~Nexus ~~STATEMENTS~~BioPharma, OFInc. ~~CASH~~(”we”, ~~FLOWS~~“our”, “NBP”, “the Company”) was incorporated in Delaware on April 17, 2013. During this time the Company devoted substantially all of its efforts to activities such as financial planning and raising capital. The Company did not have any transactions from incorporation date through the period ended February 28, 2014.

~~(Unaudited)~~NBP is a life science company focused on the development and commercialization of a pharmaceutical preparation to treat obesity and the symptoms of type 2 diabetes.

	Three monthsendedMarch 31,2016			Three monthsendedMarch 31,2015
OPERATING ACTIVITIES
Net loss for the period	$	(7,304	)	$	(20,168	)
Adjustments to reconcile net loss to net cash used in operating activities:
Expenses paid by officers		6,254			8,448
Changes in operating assets and liabilities:
Prepaid expenses		-			5,000
Accounts payable		1,050			6,720
NET CASH USED IN OPERATING ACTIVITIES		-			-
INVESTING ACTIVITIES		-			-
FINANCING ACTIVITIES		-			-
NET CHANGE IN CASH		-			-
CASH AT BEGINNING OF PERIOD		-			-
CASH AT END OF PERIOD	$	-		$	-

On February 1, 2016, the Company effected a 1 for 13.5 reverse stock split of its common stock. All share information in the financial statements for fiscal years 2016 and 2015 reflect the impact of the reverse stock split.

~~The accompanying notes are an integral part of these condensed financial statements.~~Reverse merger

6On May 17, 2016 the Company entered into an Agreement and Plan of Reorganization (“Merger Agreement”) by and among Bio Pharma, Inc. a Nevada corporation (“Nexus”), the Company and Nexus Acquisition Corp. (“Acquisition Corp.”), a Delaware corporation and wholly owned subsidiary of Nexus. The Merger Agreement closed on June 9, 2016 and resulted in the following:

~~PLATA~~Acquisition Corp. ~~RESOURCES~~merged with the Company with the latter as the surviving company in the merger. The Company shall continue its corporate existence under the name “Nexus Biopharma, ~~INC~~Inc”.

~~NOTES~~Each share TOof ~~THE~~common ~~CONDENSED~~stock ~~FINANCIAL~~of ~~STATEMENTS~~the Company prior to the merger converted into 4.8552632 shares of common stock, par value $0.001 per share, of Nexus. Nexus then cancelled 35,500,000 shares of its common stock that were outstanding prior to the merger.

~~March~~The Company’s 31stockholders shall receive convertible promissory notes corresponding to their proportional ownership interest of NBP common stock which shall be convertible into newly created shares of preferred stock of Nexus. The Nexus preferred shares shall be convertible into 36,000,000 ~~2016~~shares ~~(Unaudited)~~of Nexus common stock. The convertible notes will be issued once Nexus has the preferred shares in place.

~~NOTE~~The transaction 1is –accounted ~~NATURE~~for OFas ~~OPERATIONS~~a ~~AND~~reverse ~~BASIS~~acquisition OFand ~~PRESENTATION~~the Company is considered the accounting acquirer for financial reporting purposes. The historical consolidated financial statements include the operations of the accounting acquirer for all periods presented.

~~Nature~~Basis of ~~Operations~~Presentation

The ~~Company,~~accompanying ~~Plata~~unaudited ~~Resources,~~interim ~~Inc~~financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial statements. Accordingly, ~~was~~such ~~incorporated~~interim ~~under~~financial statements do not include all the ~~laws~~information ofand footnotes required by accounting principles generally accepted in the ~~State~~United States for complete annual financial statements. The information furnished reflects all adjustments, consisting only of ~~Nevada~~normal onrecurring ~~July~~items 17which are, ~~2007~~in ~~with~~the opinion of management, necessary in order to make the ~~authorized~~financial ~~capital~~statements ~~stock~~not misleading. The balance sheet as of February ~~750~~29,~~000~~ 2016 has been derived from the Company’s annual financial statements that were audited by an independent registered public accounting firm,~~000~~ ~~shares~~but atdoes $0not include all of the information and footnotes required for complete annual financial statements.~~001~~ The ~~par~~financial ~~value~~statements included in this Quarterly Report should be read in conjunction with the financial statements and the notes thereto included in the Company’s Report on Form 8-K/A filed on June 9, 2016.

The Company was organized for the purpose of acquiring and developing mineral properties. At the report date mineral claims, with unknown reserves, had been acquired. The Company has not yet established the existence of a commercially minable ore deposit.5

~~Basis~~NEXUS BIOPHARMA, ~~of Presentation~~INC.

~~The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for financial information and with the instructions~~ Notes to ~~Form~~Consolidated ~~10-Q.~~Financial They do not include all information and footnotes required by United States generally accepted accounting principles for complete financial statements. However, except as disclosed herein, there has been no material changes in the information disclosed in the notes to the financial statements for the year ended December 31, 2015 included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission. The unaudited financial statements should be read in conjunction with those financial statements included in the Form 10-K. In the opinion of Management, all adjustments considered necessary for a fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.Statements

~~NOTE~~August 31, 22016 –and ~~GOING CONCERN~~2015

7(Unaudited)

~~NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES~~Going Concern

~~Accounting~~These financial ~~Method~~statements have been prepared on a going concern basis. The Company has incurred losses since inception and has a working capital deficit, which raises substantial doubt about The Company’s ability to continue as a going concern. Its ability to continue as a going concern is dependent upon the Company’s ability to generate profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management has plans to seek additional capital through a private placement and public offering of its common stock. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue in existence.

~~The~~NOTE 2 ~~Company~~– ~~recognizes~~LICENSE ~~income~~AGREEMENT ~~and~~AND ~~expenses based on the accrual method of accounting.~~COMMENTMENTS

~~Dividend~~The ~~Policy~~Company entered in to a Patent and Technology License Agreement with the Albert Einstein College of Medicine in March 2014. The agreement grants the Company a world-wide exclusive license to materials and methods for use in the diagnosis and treatment of cancers, obesity and diabetes with inhibitors of Fyn kinase. In return the Company has agreed to pay a license fee, to reimburse the licensor patent expenses thus far incurred, to pay all future patent expenses, pay a royalty on any sales of product using licensed technology, as well as certain minimum royalties and milestone payments.

~~The~~Pursuant to ~~Company~~the ~~has~~License ~~not~~Agreement, ~~yet~~we ~~adopted~~are aalso ~~policy~~obligated ~~regarding~~to ~~payment~~make ofthe ~~dividends.~~following royalties and payments to the Licensors:

~~Basic~~● Royalty payment equivalent to 3% of net sales. ● Royalty payment of minimum of a specified percentage of net sales in case the Company pays royalties to unaffiliated third parties for patent rights. Pay 20% of any net proceeds that the Company will receive pursuant to a sublicense agreement that the Company will enter into with other parties. ● Issue 30% of the Company outstanding common stock to the Licensors calculated on a fully diluted, as converted basis. Accordingly, we issued 126,984 common shares valued at $857,143 which was charged to research and ~~Diluted~~development ~~Loss~~expense ~~per~~in ~~Share~~the statements of operations. ● Non-refundable license fee of $25,000 upon execution of License Agreement. ● License maintenance fee of $30,000 on each of the first, second, third and fourth anniversary of the License Agreement. The payment may be credited against royalties made during the twelve month period. ● License maintenance fee of $50,000, and $75,000 on the fifth and sixth anniversaries of the License Agreement, respectively. Each payment may be credited against royalties made during each such twelve month period. ● License maintenance fee of $100,000 on the seventh and each subsequent anniversary of the License Agreement. Each payment may be credited against royalties made during each such twelve month period. Milestone payments ranging from $100,000 to $750,000 if certain milestones are achieved.

~~The~~Additionally, ~~Company~~under ~~computes~~the ~~loss~~license ~~per~~agreement ~~share~~the Company inis ~~accordance~~obligated ~~with~~to ~~"ASC-260,"~~offer ~~"Earnings~~new ~~per~~shares ~~Share"~~to ~~which~~the ~~requires~~licensor ~~presentation~~on ofa ~~both~~fully ~~basic~~diluted ~~and~~basis ~~diluted~~for ~~earnings~~all ~~per~~new ~~share~~stock onissues with the ~~face~~sale ofterms offered under the ~~statement~~new ~~of operations~~issue. ~~Basic~~The ~~loss~~License ~~per~~Agreement ~~share~~will isterminate ~~computed~~upon byexpiration ~~dividing~~of ~~net~~the ~~loss~~patent. ~~available~~The toinitial ~~common~~payment ~~shareholders~~of by$30,000, due ~~the~~March ~~weighted~~3, ~~average~~2015 ~~number~~was ofnot ~~outstanding~~made ~~common~~and ~~shares~~the ~~during~~second ~~the~~annual ~~period.~~payment, ~~Diluted~~due ~~loss~~March ~~per~~3, ~~share~~2016 ~~gives~~was ~~effect~~not tomade. ~~all~~As ~~dilutive~~of ~~potential~~the ~~common~~date ~~shares~~of ~~outstanding~~this ~~during~~filing the Company ~~period.~~has ~~Dilutive~~not ~~loss~~received ~~per~~any ~~share~~demand ~~excludes~~for ~~all~~payment ~~common~~or ~~stock~~notice ~~equivalents~~of ifdefault ~~their~~from ~~effect~~Albert isEinstein ~~anti-dilutive~~College of Medicine. AsThe ofCompany ~~March~~plans to ~~31,~~pay ~~2016~~these ~~and~~minimum ~~2015,~~royalty ~~there~~payments ~~were~~as nosoon ~~dilutive~~as ~~common~~adequate ~~stock~~funds ~~equivalents~~are ~~outstanding~~available.

~~Use of Estimates~~6

~~The~~NEXUS BIOPHARMA, preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periodINC. ~~Actual results could differ from those estimates.~~

~~Income~~Notes to ~~Taxes~~Consolidated Financial Statements

The Company follows the liability method of accounting for income taxes in accordance with FASB accounting standards for Accounting for Income Taxes and Accounting for Uncertainty in Income Taxes. Under this methodAugust 31, ~~deferred~~2016 ~~tax assets~~ and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax balances. Deferred tax assets and liabilities are measured using enacted or substantially enacted tax rates expected to apply to the taxable income in the years in which those differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the date of enactment or substantive enactment. 2015

8(Unaudited)

~~Foreign~~NOTE 3 ~~Currency~~– ~~Translations~~RELATED PARTY TRANSACTIONS

The Company ~~books~~has ofan employment agreement with the ~~Company~~principal ~~are~~officer ~~maintained~~and stockholder providing for a base salary of $43,750 and $87,500 in ~~United~~the ~~States~~three ~~dollars~~and six months ended August 31, 2016, respectively and ~~this~~$36,250 isand $72,500 in the ~~Company's~~three ~~functional~~months and ~~reporting~~six ~~currency~~ended August 31, 2015, respectively. ~~Translations~~The ~~denominated~~base insalary ~~other~~shall ~~than~~be ~~the~~increased ~~United~~at ~~States~~the ~~dollar~~end ~~are~~of ~~translated~~each asyear ~~follows~~to ~~with~~reflect the ~~related~~change ~~transaction~~in ~~gains~~the consumer price index and ~~losses~~the ~~being~~board ~~recorded~~of directors may award increases in the ~~Statement~~base ofsalary ~~Operations:~~greater than those provided above.

~~(i)~~If the ~~Monetary~~officer ~~items~~continues ~~are~~active ~~recorded~~employment atafter ~~the~~2016, ~~rate~~compensation ofwill ~~exchange~~be ~~prevailing~~negotiated. asThe atCompany’s ~~the~~obligation ~~balance~~under ~~sheet~~the employment ~~date;~~agreement ~~(ii)~~accrues ~~Non-Monetary~~only ~~items~~as ~~including~~the ~~equity~~service ~~are~~is ~~recorded~~rendered. at. ~~the~~As ~~historical rate~~ of ~~exchange;~~August ~~and~~31, ~~(iii)~~2016 ~~Revenues~~ and ~~expenses~~2015, ~~are~~unpaid ~~recorded~~salaries atto the ~~period~~CEO ~~average~~amounted to in$193,773 ~~which~~and ~~the~~$110,100, ~~transaction occurred~~respectively.

~~Impairment~~On March 1, 2014, the Company entered into a consulting agreement with a principal stockholder providing monthly payments of ~~Long-Lived~~$5,000 plus ~~Assets~~reimbursable travel expenses for a period of six months, after which, the agreement shall automatically renew for an additional three month term unless terminated by either party with 15 day prior notice. On June 1, 2014, the Company entered into a new agreement with the principal stockholder with the same terms as the previous one except that the monthly fee was increased to $7,500. Total consulting fees incurred for the three months ended August 31, 2016 and 2015 amounted to $15,000 and $0 respectively. Total consulting fees incurred for the six months ended August 31, 2016 and 2015 amounted to $30,000 and $0, respectively.

~~The~~NOTE 4 ~~Company~~– ~~reviews~~SHORT ~~and~~TERM evaluates long-lived assets for impairment when events or changes in circumstances indicated that the related carrying amounts may not be recoverable. The assets are subject to impairment consideration under ASC 360-10-35-17 if events or circumstances indicate that their carrying amounts might not be recoverable. When the Company determines that an impairment analysis should be done, the analysis will be performed using rules of ASC 930-360-35, Asset Impairment, and 360-10-15-3 through 15-5, Impairment of Disposal of Long-Lived Assets.DEBT

~~Fair~~Short term ~~Value~~notes payable consist of ~~Financial~~an ~~Instruments~~unsecured note payable of $292,500 with an interest rate of 10% and is due in April 2017.

~~The~~NOTE 5 ~~estimated~~– ~~fair~~CONVERTIBLE ~~values~~NOTES of financial instruments were determined by management using available market information and appropriate valuation methodologies. The carrying amounts of financial instruments including cash approximate their fair value because of their short maturities. PAYABLE

~~Revenue~~Convertible notes ~~Recognition~~were issued during December 2015 and January 2016 with principal amounts totaling to $60,000. The notes are non-interest bearing and have a term of three years. The notes shall automatically convert into the Company’s planned units offering with each unit consisting of two shares of common stock and one warrant at a price of $1 per unit. An aggregate of 60,000 warrants were issued with the notes. These warrants have an exercise price of $1.50 per share and a term of 3 years. The relative fair value of the warrants amounting to $20,000 was recognized as a debt discount and amortized over the term of the notes. Amortization expense for the three and six months ended August 31, 2016 was $1,667 and $3,334, respectively.

~~The~~NOTE 6 ~~Company~~– ~~has no revenues to date from its operations. Once revenues are generated, management will establish a revenue recognition policy~~EQUITY

~~Advertising~~Common and ~~Costs~~preferred stock

The Company ~~accounts~~is ~~for~~authorized ~~its~~to ~~advertising~~issue_100,000,000 ~~cost~~shares inof ~~accordance~~common stock with ~~ASC~~a ~~720~~par value of $0.0001 ~~The~~per ~~Company~~share ~~expenses~~and ~~advertising~~50,000,000 ~~costs~~shares of aspreferred ~~incurred.~~stock, ~~For~~with ~~the~~a ~~periods~~par ~~ended~~value ~~March~~$0.00001 ~~31,~~per ~~2016~~share. ~~and~~There ~~March~~was ~~31,~~no ~~2015,~~preferred ~~the~~stock ~~Company~~outstanding ~~incurred~~as noof ~~advertising~~August ~~expenses~~31, 2016 and February 29, 2016.

9Shares for services

~~Statement~~During the six months ended August 31, 2016, the Company issued 4,457,132 (post-merger) shares of ~~Cash~~common ~~Flows~~stock for consulting services with a fair value of $91,800.

~~For~~Equity Line ~~the purposes~~ of ~~the statement of cash flows, the Company considers all highly liquid investments with a maturity of three months or less to be cash equivalents.~~Credit

~~Mineral~~The ~~Claim~~Company ~~Acquisition~~entered into an Equity Line of Credit Agreement (the “ELOC”) with Corelli Capital A.G. (“CCAG”) on June 14, 2016. The terms of the agreement provide that the Company shall issue and ~~Exploration~~sell ~~Costs~~to CCAG up to $2,250,000 of the Company’s common stock. The Company can request in separate transactions a maximum advance amount of $200,000 in exchange for the issuance of the equivalent amount of common stock valued at the current market price. The first advance amount will be calculated at $0.20 per share. The agreement will expire, either seven months from the agreement date or, when the investor shall have made the payment of advances totaling $2,250,000, whichever comes first. The Company requested an advance for $200,000 on June 22, 2016 of which $100,000 was received as of August 31, 2016 and is reported in the consolidated balance sheet as stock payable. The Company received the remaining $100,000 on September 7, 2016. Under the terms of the ELOC the Company will issue 1,000,000 shares in return for the first funding of $200,000.

Mineral property acquisition costs are initially capitalized when incurred. These costs are then assessed for impairment when factors are present to indicate the carrying costs may not be recoverable. Mineral exploration costs are expensed as incurred.Warrants

~~Environmental~~As of ~~Requirements~~August 31, 2016, the Company has an aggregate of 60,000 warrants outstanding and exercisable with a weighted average exercise price of $1.50 and a weighted average remaining term of 2.4 years.

~~At the report date environmental requirements related to the mineral claim acquired are unknown and therefore any estimate of any future cost cannot be made.~~7

~~Recent~~Item 2 ~~Accounting~~- ~~Pronouncements~~Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and the related notes to the consolidated financial statements included elsewhere in this Form 10-Q. The ~~Company~~following ~~does~~discussion ~~not~~and ~~expect~~analysis contains forward-looking statements within the ~~adoption~~meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, without limitation, statements regarding our expectations, beliefs, intentions or future strategies that are signified by the words “expect,” “anticipate,” “intend,” “believe,” or similar language. All forward-looking statements included in this document are based on information available to us on the date hereof, and we assume no obligation to update any ~~recent~~such ~~accounting~~forward-looking ~~pronouncements~~statements. Our business and financial performance are subject to ~~have~~substantial arisks ~~material~~and ~~impact~~uncertainties. Actual results could differ materially from those projected in the forward-looking statements. In evaluating our business, you should carefully consider the information set forth under the heading “Risk Factors” in the reports we file with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on ~~its~~these ~~financial~~forward-looking statements.

~~NOTE 4 – SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES~~Business Overview

~~The~~We are ~~Company's~~a ~~two~~life ~~directors~~science ~~have~~company ~~acquired~~focused ~~56%~~on the development and commercialization of ~~the~~a ~~common~~pharmaceutical ~~stock~~preparation ~~issued~~to treat obesity and the ~~outstanding~~symptoms of type 2 diabetes. ~~During~~For ~~the~~our ~~three~~first ~~months~~product ~~ended~~opportunity ~~March~~we ~~31,~~have ~~2016~~engaged ~~and~~Charles ~~2015,~~River Laboratories for the ~~Company's~~discovery of ~~two~~a ~~directors~~small ~~paid~~molecule ~~expenses~~drug onthat ~~behalf~~activates ofmetabolic pathways to increase energy expenditure. In completed animal trials our proprietary approach to the ~~Company~~pharmaceutical activation of ~~$6,254~~this ~~and~~LKB-1 ~~$8,448,~~AMPK ~~respectively~~ (~~reported~~Adenosine asMonophosphate ~~advances~~dependent Protein ~~from~~Kinase) ~~related~~pathway ~~parties~~resulted onin ~~the~~increased ~~balance~~energy ~~sheet).~~expenditure, ~~Advances~~decreased ~~from~~fat ~~related~~mass ~~parties~~and ~~are~~resulting ~~non-interest~~weight ~~bearing~~loss, lower blood glucose, improved insulin sensitivity, lower cholesterol, and ~~payable~~lower onblood ~~demand~~triglyceride levels.

10Unlike most other FDA approved weight loss drugs, our strategy does not depend on a pharmaco-neurological manipulation of the higher-brain centers for appetite and/or satiety. Rather, our proprietary drug approach targets the master energy regulatory pathway that has been proven to exist not only in higher mammals, but also in all living cells that possess a nucleus. Because an intensive aerobic and resistance strength-training regime is the natural way to activate these pathway effects, we believe that our drug will help obese patients mimic the effect of a more healthy lifestyle and lose weight.

~~ITEM~~We believe that a drug that will step up the body’s metabolism of fat will address the biggest health problem in the world, obesity. Obesity is also implicated as a causative and an additive to a host of other conditions, the most important of which are Type 2 diabetes, cardiovascular disease and cancer. ~~MANAGEMENT'S~~Type ~~DISCUSSION~~II ~~AND~~diabetes, ~~ANALYSIS~~which OFnow ~~FINANCIAL~~consumes ~~CONDITION~~roughly ~~AND~~one ~~RESULTS~~sixth OFof ~~OPERATIONS~~every health care dollar in America, is a direct result of obesity.

~~Our~~Financial Operations Form 10-Q includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this Form 10- Q. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions.Overview

~~The~~Upon commercialization ~~following~~of ~~discussion~~the ~~should~~Company’s beobesity ~~read~~therapeutic, inwe ~~conjunction~~will begin working with ~~the~~third-party ~~information~~payors ~~contained~~to inestablish ~~the~~reimbursement coverage ~~financial~~policies. Where ~~statements~~policies ofare ~~Plata~~not ~~Resources~~in place, ~~Inc~~we will pursue case-by-case reimbursement. We believe that as much as 20% of our future revenues may be derived from product(~~"Plata"~~s) "billed to Medicare. We" orwill ~~the~~begin ~~"Company")~~working ~~and~~with ~~the~~many ~~notes~~payors, including Medicare, to establish policy-level reimbursement, which, ~~form~~if in place, will allow us to recognize revenues upon submitting an invoice. We ~~integral~~do ~~part~~not ofexpect to recognize the ~~financial~~majority ~~statements~~of ~~which~~revenues ~~are~~in ~~attached~~this ~~hereto~~manner until calendar 2022, at the earliest.

~~The~~Since ~~financial~~our ~~statements~~inception, ~~mentioned~~we ~~above~~ have ~~been~~generated ~~prepared~~significant net inlosses. ~~conformity~~As ~~with~~of ~~accounting~~August ~~principles~~31, ~~generally~~2016, ~~accepted~~we had an accumulated deficit of $3,047,345. We incurred net losses of $179,340 and $768,722 in the ~~United~~three ~~States~~months ended August 31, 2016 and 2015, respectively and $438,998 and $914,173 for the six months ended August 31, 2016 and 2015, respectively. We expect our net losses to continue for at least the next several years. We anticipate that a substantial portion of ~~America~~our capital resources and ~~are~~efforts ~~stated~~will be focused on research and development, both to develop our initial obesity therapeutic and to develop additional products for obesity and type 2 diabetes, scale up our commercial organization, and other general corporate purposes. Our financial results will be limited by a number of factors, including establishment of coverage policies by third-party insurers and government payors, our ability in ~~United~~the ~~States~~short ~~dollars~~term to collect from payors often requiring a case-by-case manual appeals process, and our ability to recognize revenues other than from cash collections on therapeutics billed until such time as reimbursement policies or contracts are in effect. Until we receive routine reimbursement and are able to record revenues as therapeutics are prescribed and delivered, we are likely to continue reporting net losses.

~~Our Company was formed under the laws of the State of Nevada on July 17, 2007.~~8

~~Our~~Critical Accounting ~~offices~~Policies ~~are~~and ~~located~~Significant atJudgments ~~2911 Park Avenue, Pasay City, Metro Manila, Philippines~~ and ~~can be reached at 632-886-788.~~Estimates

This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as revenues and expenses during the reporting periods. We ~~are~~evaluate our estimates and judgments on an ~~Emerging~~ongoing ~~Growth~~basis. We ~~Company~~base asour estimates ~~defined~~on inhistorical experience and on various other factors we believe are reasonable under the ~~Jumpstart~~circumstances, ~~Our~~the ~~Business~~results of ~~Startups~~which ~~Act~~form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from those estimates under different assumptions or conditions.

We believe ~~shall~~the ~~continue~~following tocritical beaccounting ~~deemed~~policies anreflect ~~emerging~~our ~~growth~~more ~~company~~significant ~~until~~estimates ~~the~~and ~~earliest~~assumptions used in the preparation of— our financial statements.

(A) the last day of the fiscal year of the issuer during which it had total annual gross revenues of $1,000,000,000 (as such amount is indexed for inflation every 5 years by the Commission to reflect the change in the Consumer Price Index for All Urban Consumers published by the Bureau of Labor Statistics, setting the threshold to the nearest 1,000,000) or more;Revenue Recognition

~~(B)~~We have ~~the~~generated ~~last~~no ~~day~~revenues ofsince ~~the~~our ~~fiscal~~inception. Product ~~year~~revenues offor ~~the~~our ~~issuer~~first ~~following~~product, ~~the~~our ~~fifth~~therapeutic ~~anniversary~~for the treatment of ~~the~~obesity, ~~date~~are ofexpected to be generated from the ~~first~~projected ~~sale~~commercial oflaunch ~~common~~in ~~equity~~2022, ~~securities~~and are expected to be recognized on a cash basis because we will have limited collection experience and a limited number of ~~the~~contracts. In ~~issuer~~accordance ~~pursuant~~with our topolicy, revenues for tests therapeutic prescribed will be recognized on an ~~effective~~accrual ~~registration~~basis ~~statement~~when ~~under~~the ~~this~~related ~~title;~~costs are incurred, provided there is a contract or coverage policy in place and the following criteria are met:

~~(C)~~● ~~the~~persuasive ~~date~~evidence onthat ~~which~~an ~~such~~arrangement ~~issuer~~exists; ● delivery has, ~~during~~occurred or services rendered; ● the ~~previous~~fee ~~3-year~~is ~~period,~~fixed ~~issued~~and ~~more~~determinable; ~~than~~and ~~$1,000,000,000~~● incollectability ~~non-convertible~~is ~~debt;~~reasonably orassured.

~~(D)~~Determination of the ~~date~~last ontwo ~~which~~criteria ~~such~~will ~~issuer is deemed to~~ be abased ~~'large~~on ~~accelerated~~management’s ~~filer',~~judgment asregarding ~~defined~~the innature ~~section~~of ~~240.12b-2~~the offee ~~title~~charged ~~17,~~for ~~Code~~products ofor services ~~Federal~~delivered ~~Regulations,~~and orthe ~~any~~collectability ~~successor~~of ~~thereto~~those fees.

AsWe expect anto ~~emerging~~generally ~~growth~~bill ~~company~~third-party wepayors ~~are~~for ~~exempt~~our ~~from~~obesity ~~Section~~therapeutic ~~404(b)~~upon the filling of ~~Sarbanes~~a ~~Oxley~~patient prescription. Accordingly, we ~~Section~~take ~~404(a)~~assignment ~~requires~~of ~~Issuers~~benefits toand ~~publish~~the ~~information~~risk inof ~~their~~collection ~~annual~~with ~~reports~~the ~~concerning~~third-party payor. We usually bill the ~~scope~~patient ~~and~~directly ~~adequacy~~for amounts ofowed after multiple requests for payment have been denied or only partially paid by the ~~internal~~insurance ~~control~~carrier. ~~structure~~As a new drug, our obesity therapeutic may be considered investigational by payors and ~~procedures~~not ~~for~~covered ~~financial~~under ~~reporting~~their reimbursement policies. Consequently, we ~~This~~expect ~~statement~~to ~~shall~~pursue ~~also~~case-by-case ~~assess~~reimbursement ~~the~~where ~~effectiveness~~policies ofare ~~such~~not ~~internal~~in ~~controls~~place ~~and~~or ~~procedures~~payment history has not been established.

11Contract revenues are expected to be derived from studies conducted with biopharmaceutical and pharmaceutical companies and will be recognized on a contract specific basis. Under certain contracts, our input, measured in terms of full-time equivalent level of effort or running a set of assays through our laboratory under a contractual protocol, will trigger payment obligations and revenues will be recognized as costs are incurred or assays are processed. Certain contracts May have payment obligations that are triggered as milestones are complete, such as completion of a successful set of experiments. In these cases, revenues are recognized when the milestones are achieved.

Section 404(b) requires that the registered accounting firm shall, in the same report, attest to and report on the assessment on the effectiveness of the internal control structure and procedures for financial reporting.9

AsClinical anCollaborator ~~emerging growth company we are exempt from Section 14A and B of the Securities Exchange Act of 1934 which require the shareholder approval of executive compensation and golden parachutes.~~Costs

We ~~have~~expect ~~irrevocably~~to ~~opted~~enter ~~out~~into ofcollaboration and ~~the~~clinical ~~extended~~trial ~~transition~~agreements ~~period~~with ~~for~~clinical ~~complying~~collaborators ~~with~~and ~~new~~record orthese ~~revised~~costs ~~accounting~~as ~~standards~~research ~~pursuant~~and development expenses. We plan to ~~Section~~record ~~107(b)~~accruals for estimated study costs comprised of ~~the~~work ~~Act~~performed by our collaborators under contract terms. All clinical collaborators will be expected to enter into agreements with us, which specify work content and payment terms.

WeResults ~~were incorporated on July 17, 2007 under the laws~~ of the State of Nevada. We are engaged in the search of mineral deposits or reserves but are not in either the development or production stage. It might take us years before we are able to be in either the development or production stage and the chances are that we might never be in either of these two stages. Our mineral property is called the Bontoc Gold Claim (the "Bontoc Claim") and is located in the Philippines. We own 100% of the Bontoc Claim. It consists of one – 9 unit claim block containing 102.5 hectares which have been staked and recorded with the Mineral Resources Department of the Ministry of Energy and Mineral Resources of the Government of the Republic of Philippines.Operations

WeComparison ~~have~~of nothe ~~revenue,~~Three ~~have~~and ~~achieved~~Six ~~losses~~Months Ended ~~since~~August ~~inception~~31, ~~have~~2016 ~~no operations~~ and ~~have~~August ~~relied~~31, ~~upon the sale of our securities and loans from our officers and directors to fund our operations.~~2015

~~Our~~Revenues. There ~~administrative~~were no ~~office~~revenues isfor ~~located~~the atthree ~~2911~~and ~~Park~~six ~~Avenue,~~months ~~Pasay~~ended ~~City,~~August ~~Metro Manila~~31, ~~Philippines~~2016 ~~(Tel: 632-886-788)~~ and ~~our~~August ~~registered~~31, ~~statutory~~2015, ~~office~~respectively, isbecause ~~located~~we athave ~~Suite~~not ~~129~~yet –commercialized our ~~123~~obesity ~~W Nye Lane, Carson City, Nevada, 89706~~therapeutic.

~~Plata~~Cost ~~Resources~~of ~~presently~~Product ~~has~~Revenues. No cost ~~minimal~~of ~~day-to-day~~product ~~operations;~~revenues ~~mainly~~were ~~comprising~~recorded ~~the~~in ~~maintaining of~~ the ~~Bontoc~~three ~~Claim~~months inand ~~good~~six ~~standing~~months onended anAugust ~~annual~~31, ~~basis~~2016 and ~~preparing~~August ~~the~~31, ~~various~~2015, ~~reports~~respectively, because we tohave benot ~~filed~~yet ~~with~~commercialized ~~the~~our ~~United~~obesity ~~States Securities and Exchange Commission (the "SEC") as required~~therapeutic.

~~Our~~General ~~Company~~and ~~does~~Administrative ~~not~~Expenses. General and ~~have~~administrative ~~any~~expenses ~~subsidiaries.~~totaled ~~Our~~$161,403 ~~Company~~for ~~has~~the nothree ~~current~~months ~~plans~~ended August 31, ~~proposals~~2016 oras ~~arrangement~~compared to $761,222 ~~written~~for orthe ~~otherwise~~three months ended August 31, 2015. General and administrative expenses totaled $409,417 for the six months ended August 31, 2016 as compared to ~~seek~~$803,273 for the six months ended August 31, 2015. This represents a ~~business~~decrease ~~combination~~of ~~with~~$599,819 ~~another~~for ~~entity~~the three months and $393,856 for the six months ended August 31, 2016. This decrease was due in part to stock based compensation of $625,000 in the 2015 period versus no stock based compensation costs and normal costs for legal, accounting and other professional costs in the 2016 period.

~~LIQUIDITY~~Research ~~AND~~and ~~CAPITAL~~Development ~~RESOURCES~~Expenses. Research and development expenses were $8,904 for the three months ended August 31, 2016 as compared to $7,500 for the three months ended August 31, 2015. Research and development expenses were $16,404 for the six months ended August 31, 2016 as compared to $110,900 for the six months ended August 31, 2015. This represents an increase of $1,404 for the three months ended August 31, 2016 over the three months ended August 31, 2015 versus a decrease of 94,496 over the six month period. This three month increase was primarily as a result of payment of license associated fees to Albert Einstein College of Medicine, Inc. The six month decrease was a result of decreased R&D activity during the period.

AsInterest Expense, Net. We recorded $7 of ~~March~~interest ~~31,~~income ~~2016,~~during wethe ~~had~~three $0months inended ~~cash~~August as31, ~~compared~~2016 toand $0 induring ~~cash~~the atthree ~~December~~months ended August 31, 2015, respectively. ~~Plata~~We ~~Resources~~recorded ~~has~~$9,040 ~~had~~of nointerest ~~revenue~~expense ~~since~~during ~~inception~~the ~~and~~three ~~its~~months ~~accumulated~~ended ~~deficit~~August is31, 2016 and $~~198,421.~~0 Toduring ~~date,~~the ~~Plata~~six ~~Resources~~months ended ~~has~~August ~~been~~31, ~~funded~~2015, byrespectively. ~~the~~We ~~sale~~recorded $13,191 of ~~shares~~interest ~~and~~expense ~~advances~~during bythe ~~its~~six ~~directors~~months inended August ~~order~~31, to2016 ~~meet~~and $0 during the ~~requirements~~six ofmonths ~~filing~~ended ~~with~~August ~~the~~31, ~~SEC~~2015, respectively.

~~The~~Net ~~plan~~Loss. As a result of ~~operations~~the ~~during~~factors ~~the~~described ~~next~~above, ~~twelve~~we ~~months~~had isa net loss of $179,340 for usthe three months ended August 31, 2016 as compared to ~~explore~~$768,722 for the ~~Bontoc~~three ~~Claim~~months asended ~~recommended~~August by31, ~~Geraldo~~2015. ~~Peralta~~As ~~and~~a ~~maintain~~result of the ~~Company~~factors indescribed ~~good~~above, ~~standing~~we ~~with~~had ~~the~~a ~~regulatory~~net ~~authorities~~loss of $438,998 for the ~~next~~six months ~~several~~ended ~~years.~~August ~~Presently~~31, we2016 doas ~~not~~compared ~~have~~to ~~the~~$914,173 ~~funds~~for tothe ~~consider~~six ~~any~~months ~~additional~~ended ~~mineral~~August ~~claims~~31, 2015.

1210

~~RESULTS~~Liquidity and OFCapital ~~OPERATIONS~~Resources

~~For~~Since our ~~the three month period ended March 31~~inception, ~~2016~~ we ~~had~~have noincurred ~~revenue.~~significant ~~Expenses~~losses ~~for this period totaled $7~~and,~~304~~ as ~~compared~~of toAugust ~~expenses for the three month period ended March~~ 31, ~~2015 of $20~~2016,~~168~~ ~~resulting~~we inhad aan ~~net~~accumulated ~~loss~~deficit of $73,~~304~~047,345. We have ~~for~~not ~~the~~yet ~~three~~achieved ~~month~~profitability ~~period~~and ~~ended~~anticipate ~~March~~that ~~31,~~we ~~2016~~will ascontinue ~~compared~~ to aincur net ~~loss~~losses ~~of $20,168~~ for the ~~three~~foreseeable ~~month~~future. We expect ~~period~~that ~~ended~~our ~~March~~research 31and development, ~~2015.~~general ~~The~~and ~~net~~administrative ~~loss~~and ~~for~~selling ~~the~~and ~~three~~marketing ~~months~~expenses ~~ended~~will ~~March~~continue ~~31,~~to ~~2016~~grow and, ~~was~~as ~~the~~a result, ofwe ~~general~~will ~~and~~need ~~administrative~~to ~~expenses~~generate ~~totaling~~significant ~~$7,304~~product asrevenues ~~compared~~ to ~~general~~achieve ~~and~~profitability. ~~administrative~~We ~~expenses~~may ofnever ~~$20,168~~achieve ~~for the three months ended March 31, 2015~~profitability.

~~Our~~Sources of ~~Mineral Property~~Liquidity

~~Plata~~Since our ~~has~~inception, ~~purchased~~our aoperations ~~100%~~have ~~interest~~been infinanced through the ~~Bontoc~~sale ~~Claim~~of our common stock and issuance of debt. ~~Our~~Through ~~claim~~August ~~consists~~31, 2016, we had received net proceeds of ~~one~~approximately –$310,801 9through ~~unit~~the ~~claim~~sale ~~block~~of ~~containing~~our ~~102.5~~common ~~hectares~~stock ~~which~~to ~~have~~investors. In December ~~been~~of ~~staked~~2015 and ~~recorded~~January of 2016 we entered into a Convertible Note Agreement with ~~the~~two ~~Mineral~~investors ~~Resources~~for ~~Department~~a total of $60,000. On April 20, 2016 we entered into an unsecured promissory note with Corelli Capital A.G. for the ~~Ministry~~sum of ~~Energy~~$292,500.00. ~~and~~We ~~Mineral~~entered ~~Resources~~into an Equity Line of ~~the~~Credit ~~Government~~Agreement with Corelli Capital A.G. on July 12, 2016. As of ~~the~~August ~~Republic~~31, 2016, we had cash and cash equivalents, of ~~Philippines~~$62,441.

The Bontoc Claim was staked to cover gold zones within the claim boundaries. Previous exploration work to investigate the mineral potential of the Bontoc Claim has outlined some favorable areas for continued exploration and development.Cash Flows

~~Description~~As of August 31, 2016, we had $62,441 in cash and ~~Location~~cash equivalents, compared to $0 on August 31, 2015.

~~Bontoc~~Net ~~Claim~~cash ~~consists~~used ofin 1operating ~~unpatented~~activities ~~mineral~~was ~~claim~~$331,734 for ~~located 23 kilometers Southeast of~~ the ~~city~~six ofmonths ~~Bontoc~~ended atAugust ~~UTM~~31, ~~co-ordinates~~2016, ~~Latitude~~compared ~~17°07'00"N and Longitude 120°58'00"E. The mineral claim was assigned~~ to ~~Plata~~$22,052 byfor ~~Castillo Explorations LLC and~~ the ~~said~~six ~~assignment~~months ~~was~~ended ~~filed~~August ~~with~~31, ~~the~~2015. ~~Mineral~~The ~~Resources~~increase ~~Department~~in ofcash ~~the~~used was ~~Ministry~~primarily ofdue ~~Energy~~to ~~and~~increased ~~Mineral~~operating ~~Resources of the Government of the Republic of the Philippines~~expenses.

~~Accessibility~~Net cash used in investing activities was $8,250 for ~~Climate~~the six months ended August 31, ~~Local~~2016, ~~Resources~~compared to $0 for the six months ended August 31, ~~Infrastructure~~2015. We expect amounts used in investing activities to increase in fiscal year 2017 and ~~Topography~~beyond as we expand research and development activities and establish our proposed commercial laboratory.

~~Bontoc~~Net ~~Gold~~cash ~~Claim~~provided isby ~~accessible~~financing ~~from~~activities during the ~~city~~six ofmonths ~~Bontoc~~ended byAugust ~~traveling~~31, on2016 ~~the~~was ~~country's~~$392,500, ~~only~~compared ~~highway~~to ~~system~~$0 ~~which~~ for the ~~most~~six ~~part~~months ~~consists~~ended ofAugust ~~one lane in each direction and by taking an all weather gravel road. The province is nestled deep in the Cordillera mountain range. Landlocked~~31, ~~it is bounded by the mountains of Benguet on the west and those of the Mountain Province in the north~~2015. This ~~The terrain~~ is ~~mountainous,~~mainly due ~~sloping~~to ~~into~~proceeds ~~gently~~received ~~rolling~~from ~~hills~~notes ~~and~~payable ~~plateaus. Its mountain ranges reach an elevation of 2,523 meters above sea level. V-shaped gullies, creeks, streams~~ and ~~U-shaped rivers drain through~~ the ~~valleys.~~equity Itline ~~is the premier mining district. Some 80%~~ of ~~the~~credit ~~total~~with ~~Philippine~~Corelli ~~gold~~Capital ~~production comes from the Cordillera~~A.G.

The Philippines is situated between 5 and 22 degrees North latitude. This means the country falls within the so-called tropical climate zone, a zone characterized by high temperatures the whole year round, relatively high rainfall and lush vegetation. Rainfall on the city can occur in every month, but the wettest months are October, November and December. Annual rainfall is approximately 1.5 meters. Due to the steep, deforested, mountains on average 60 percent of the rainwater runs off fast to the sea. The remaining 40 percent partly evaporates and partly seeps through to the island's underground water aquifier.Contractual Obligations

~~Bontoc~~As of ~~has~~August ~~an experienced work force and will provide all the necessary services needed for an exploration and development operation~~31, ~~including police~~2016, ~~hospitals,~~we ~~groceries,~~had ~~fuel,~~the ~~helicopter~~following ~~services,~~contractual ~~hardware and other necessary items. Drilling companies and assay facilities are present in Bontoc.~~commitments:

13We are required to make a series of annual minimum royalty payments under the License Agreement with Albert Einstein College of Medicine beginning on the first anniversary date, or March 3, 2015. The initial payment of $30,000, due March 3, 2015 was not made and the second annual payment, due March 3, 2016 was not made. As of the date of this filing the Company has not received any demand for payment or notice of default from Albert Einstein College of Medicine. The Company plans to pay these minimum royalty payments as soon as adequate funds are available.

~~History~~For a period of seven years on each anniversary of the first payment, we are required to make additional payments in amounts that gradually increase beginning in year five. We are required to make additional payments of $30,000 in each of 2017 and 2018 and $50,000 in 2019, $75,000 in 2020, and $100,000 in 2021 and every year the License is in effect thereafter.

~~Deposits~~Beginning in ofthe ~~shell~~second ~~and~~half ~~eroded~~of ~~sand~~calendar ~~formed~~2017, ~~the~~we ~~basis~~intend ~~for~~to ~~the~~enter ~~limestone,~~into ~~which~~arrangements ~~makes~~for upthe ~~most~~acquisition of ~~Philippines.~~laboratory ~~This limestone was~~equipment, ~~over~~computer hardware ~~the~~and ~~ages~~software, ~~pushed~~leasehold ~~upwards,~~improvements ~~making~~and itoffice ~~possible to find today sea fossils high in the country's mountains~~equipment. We ~~This~~cannot ~~pushing~~at upthis ~~continues~~time ~~today.~~provide Itassurances isthat ~~caused~~we bywill be ~~the~~able ~~fact~~to ~~that~~enter ~~the~~into ~~Philippine~~agreements ~~Plate,~~with vendors on ~~which~~terms ~~most~~commercially offavorable ~~the~~to ~~country~~us ~~lies,~~or isthat ~~slowly~~we ~~diving~~will ~~under~~be ~~the~~able ~~Eurasian~~to ~~Plate~~enter ofinto ~~the~~such arrangements ~~mainland~~without ofsecuring ~~Asia~~additional financing.

~~The~~We currently ~~Philippines~~lease isapproximately ~~characterized by steep mountains without any substantial forest cover. Highest peaks reach over 1~~3,000 ~~meters.~~square ~~The~~feet ~~island~~of isadministrative ~~300 km long~~ and 35office kmspace ~~wide.~~on ~~High,~~a ~~steep~~month-to-month ~~mountains,~~basis ~~short~~for ~~distances~~an ~~and~~annual ~~lack~~ cost of ~~forest~~$25.00 ~~cover~~per ~~mean~~square ~~that rainwater runs fast to the sea, causing substantial erosion~~foot.

~~The island has vast copper, gold and coal reserves which are mined mainly in the central part.~~11

~~Plata~~Operating Capital isand ~~preparing~~Capital toExpenditure ~~conduct preliminary exploration work on its claim.~~Requirements

~~Regional~~We expect ~~Geology~~to continue to incur substantial operating losses in the future and to make capital expenditures to keep pace with the expansion of our research and development programs, which we expect to fund in part with the ~~Area~~proceeds of private placements of our securities. It may take several years to move any one of a number of product candidates in clinical research through the development phase and validation phase to commercialization. We expect that the proceeds from the sale of our securities and our existing cash and cash equivalents will be used to fund working capital and for capital expenditures and other general corporate purposes, such as licensing technology rights, partnering arrangements, or reduction of debt obligations. However, there can be no assurance that we will be able obtain financing, if at all or upon terms that will be acceptable to us.

~~The~~As a ~~hilly~~result ~~terrains~~of ~~and~~ the ~~middle~~recent ~~level~~economic ~~plain contain crystalline hard rocks such as charnockites~~recession, ~~granite gneiss, khondalites, leptynites, metamorphic gneisses with detached occurrences of crystalline limestone, iron ore, quartzo-feldspathic veins~~ and ~~basic~~the ~~intrusives~~continuing ~~such~~economic ~~as dolerites and anorthosites. Coastal zones contain sedimentary limestones~~uncertainty, ~~clay,~~it ~~laterites,~~has ~~heavy~~been ~~mineral~~difficult ~~sands~~for ~~and~~companies ~~silica~~to ~~sands.~~obtain equity ~~The~~or ~~hill~~debt ~~ranges are sporadically capped with laterites and bauxites of residual nature~~financing. ~~Gypsum~~While ~~and phosphatic nodules occur as sedimentary veins in rocks of~~ the ~~cretaceous~~credit ~~age.~~markets ~~Gypsum~~have ofimproved ~~secondary~~over ~~replacement occurs in some of~~ the ~~areas~~last ~~adjoining~~year, ~~the~~it ~~foot~~remains ~~hills~~difficult ~~of the Western Ghats. Lignite occurs as sedimentary beds of tertiary age. The Black Granite and other hard rocks are amenable~~ for ~~high~~smaller ~~polish.~~companies to ~~These~~obtain ~~granites~~financing ~~occur~~on inreasonable ~~most of the districts except the coastal area~~terms.

~~Stratigraphy~~The amount and timing of our actual expenditures vary significantly depending upon a number of factors, such as the progress of our product development, regulatory requirements, commercialization efforts, the amount of cash used by operations and progress in reimbursement. We expect that we will receive limited payments for our weight loss drug billings from the beginning of our marketing efforts into the foreseeable future. As reimbursement contracts with third-party payors are put into place, we expect an increase in the number and level of payments received for our weight loss drug billings.

~~The~~We currently ~~principal~~anticipate ~~bedded~~that ~~rocks~~our ~~for~~cash ~~the~~on ~~area~~hand as well as drawdowns from our Equity Line of ~~Bontoc~~Credit ~~Claim~~Agreement (~~and~~see “Sources of Liquidity”) will be sufficient to fund our operations for ~~most~~at ofleast the ~~Philippines~~next ~~for~~12 months. We ~~that~~cannot ~~matter)~~be ~~are~~certain ~~Precambrian~~that any ~~rocks~~of ~~which~~our ~~are~~future ~~exposed~~efforts ~~along~~to asecure ~~wide~~reimbursement ~~axial~~contract ~~zone~~programs or development of future products will be successful or that we will be able to raise sufficient additional funds to see these programs through to a ~~broad~~successful ~~complex~~result.

~~Intrusive~~Our future funding requirements will depend on many factors, including the following:

In● ~~general~~ the ~~volcanoes~~rate ~~culminate with effluents~~ of ~~hydrothermal~~progress ~~solutions that carry precious metals~~ in ~~the~~establishing ~~form~~reimbursement ofarrangements ~~naked~~with ~~elements,~~third-party ~~oxides or sulphides.~~payors;

~~These~~● ~~hydrothermal solutions intrude into~~ the ~~older~~cost ~~rocks~~of asexpanding ~~quartz~~our ~~veins.~~commercial ~~These~~operations, ~~rocks~~including ~~may~~our beselling ~~broken due to mechanical~~ and ~~chemical~~marketing ~~weathering into sand size particles and carried by streams and channels. Gold occurs also in these sands as placers.~~efforts;

~~Recent~~● ~~exploration~~the ~~result~~rate ~~for~~of ~~gold~~progress ~~occurrence~~and incost ~~Bontoc,~~of ~~Mountain~~research ~~Province is highly encouraging. Gold belt in sheared gneissic rocks is found in three subparallel auriferous load zones where some blocks having 250 to 500 metre length~~ and ~~1.5~~development toactivities 2associated ~~metre~~with ~~width~~expansion ~~could~~of beour ~~identified as most promising ones.~~products;

14● the rate of progress and cost of research and development activities associated with products in the research phase focused on neurodegenerative disease;

~~Structure~~● the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

~~(a)~~● ~~Depositional~~the ~~Environment/Geological~~effect ~~Settings:~~of competing technological and market developments;

~~Veins~~● ~~form~~the cost and delays in ~~high-grade,~~product ~~dynamothermal~~development ~~metamorphic~~as ~~environment~~a ~~where~~result ~~metasedimentary~~of ~~belts~~any ~~are~~changes ~~invaded~~in byregulatory ~~igneous~~oversight ~~rocks.~~applicable to our products; and

~~(b)~~● ~~Host/Associated~~the ~~Rock~~economic ~~Types:~~and other terms and timing of any collaborations, licensing or other arrangements into which we may enter.

~~Hosted~~Until we bycan ~~paragneisses~~generate a sufficient amount of product revenues to finance our cash requirements, ~~quartzites~~which we may never do, ~~clinopyroxenites~~we expect to finance future cash needs primarily through public or private equity offerings, ~~wollastonite-rich~~debt ~~rocks~~financings, ~~pegmatites~~borrowings or strategic collaborations. The issuance ~~Other~~of ~~associated~~equity ~~rocks~~securities ~~are~~may ~~charnockites,~~result ~~granitic~~in ~~and~~dilution ~~intermediate~~to ~~intrusive~~stockholders. We ~~rocks,~~do ~~quartz-mica~~not ~~schists~~know whether additional funding will be available on acceptable terms, ~~granulites~~or at all. If we are not able to secure additional funding when needed, ~~aplites~~we may have to delay, ~~marbles~~reduce the scope of or eliminate one or more research and development programs or selling and marketing initiatives. In addition, ~~amphibolites~~we may have to work with a partner on one or more of our product development programs or market development programs, ~~magnetite-graphite~~which ~~iron~~would lower ~~formations~~the ~~and~~economic ~~anorthosites~~value of those programs to our company.

~~(c) Tectonic Setting(s):~~12

~~Katazone~~Item 4 ~~(relatively deep, high~~-~~grade~~ ~~metamorphic~~Controls ~~environments~~and ~~associated with igneous activity; conditions that are common in the shield areas).~~Procedures

~~Deposit~~Evaluation of ~~Types~~Disclosure Controls and Procedures

~~Deposits~~The Company’s ~~are~~Principal ~~from~~Executive aOfficer ~~few~~and ~~millimetres~~Principal toFinancial ~~over~~Officer ahave ~~metre~~evaluated ~~thick~~the ineffectiveness ~~places.~~of ~~Individual~~our ~~veins~~disclosure controls ~~display~~and aprocedures ~~variety~~as of ~~forms,~~the ~~including~~end ~~saddle~~of the period covered by this report pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 (the “Exchange Act”). Based on that evaluation, ~~pod-~~the orCompany’s ~~lens-shaped~~Chief Executive Officer and Chief Financial Officer have concluded that, ~~tabular~~as orof ~~irregular~~the ~~bodies;~~end ~~frequently~~of ~~forming~~the ~~anastomosing~~period covered by this report, our disclosure controls and procedures are not effective in ensuring that information required to be disclosed in the reports that we file or ~~stockwork~~submit ~~patterns.~~under ~~Mineralization~~the Exchange Act is ~~located~~(1) recorded, processed, summarized and reported within athe ~~large~~periods specified ~~fractured~~in ~~block~~the ~~created~~Commission’s ~~where~~rules ~~prominent~~and ~~northwest-striking~~forms, ~~shears~~and ~~intersect~~(2) ~~the~~accumulated ~~north~~and ~~striking~~communicated ~~caldera~~to ~~fault~~our ~~zone~~management, including our Chief Executive Officer and Chief Financial Officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. The ~~major~~conclusion ~~lodes~~that ~~cover~~our andisclosure ~~area~~controls and procedures were not effective was due to the presence of 2the kmfollowing ~~and~~material weaknesses in internal control over financial reporting which are ~~mostly~~indicative ~~within~~of ~~400m~~many small companies with small staff: (i) no segregation of duties in incompatible functions; and (ii) lack of controls over the ~~surface~~financial process, specifically, there are no multiple levels of review. ~~Lodes~~Management ~~occur~~anticipates inthat ~~three~~such ~~main~~disclosure ~~structural~~controls ~~settings:~~and procedures will not be effective until the material weaknesses are remediated.

~~(i)~~Changes in ~~steeply~~Internal ~~dipping~~Control ~~northweststriking~~over ~~shears;~~Financial ~~(ii) flatdipping (1040) fractures (flatmakes); and (iii) shatter blocks between shears.~~Reporting

~~Most~~We have ofnot ~~the~~made ~~gold~~a ~~occurs~~change in ~~tellurides~~our internal control over financial reporting (as defined in Rules 13a-15(f) and ~~there~~15d-15(f) ~~are~~under ~~also~~the Exchange ~~significant~~Act) ~~quantities~~during ofthe ~~gold~~fiscal inquarter ~~pyrite~~ended August 31, 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

1513

~~Mineralization~~PART II - OTHER INFORMATION

NoItem 1 ~~mineralization~~- ~~has~~Legal ~~been~~Proceedings ~~reported for the area of the property but structures and shear zones affiliated with mineralization on adjacent properties pass through it.~~

~~Exploration~~To the best of our knowledge, we are not a party to any legal proceedings that, individually or in the aggregate, are deemed to be material to our financial condition or results of operations.

~~Previous~~Item 1A ~~exploration~~- ~~work~~Risk ~~on the Bontoc Claim has not been recorded if it was ever done. Governmental records indicate that no detailed exploration has been completed on the property.~~Factors

~~Property Geology~~Not applicable

ToItem 2 ~~the~~- ~~east~~Unregistered ofSales ~~the property is intrusives consisting~~ of ~~rocks~~Equity ~~such~~Securities ~~as tonalite, monzonite,~~ and ~~gabbro~~Use ~~while the property itself is underlain by sediments and volcanics. The intrusives also consist~~ of ~~a large mass of granodiorite towards the western most point of the property.~~Proceeds

~~The~~During ~~area~~the ~~consists~~quarter, ofthe ~~interlayered~~Company ~~chert~~sold 500,000 ~~argillite~~shares of ~~and~~its ~~massive~~common ~~andesitic~~stock tounder ~~basaltic~~the ~~volcanics.~~Equity ~~The~~Line ~~volcanics~~of ~~are~~Credit ~~hornfelsed,~~Agreement ~~commonly~~at ~~contain~~a ~~minor~~price ~~pyrite,~~of ~~-pyrrhotite~~$. 20 per share for gross proceeds of $100,000.

~~Drilling~~The ~~Summary~~issuance of the shares of common stock was deemed to be exempt from the registration requirements of the Securities Act of 1933, as amended, by virtue of Section 4(a)(2) thereof, as a transaction by an issuer not involving a public offering.

NoItem 3 ~~drilling~~- isDefaults Upon ~~reported~~Senior ~~on the Bontoc Claim.~~Securities

~~Sample~~No disclosure ~~Method, Sample Preparation, Data Verification~~required.

~~All~~Item 4 ~~the~~- ~~exploration~~Mine ~~conducted~~Safety to date has been conducted according to generally accepted exploration procedures with methods and preparation that are consistent with generally accepted exploration practices. No opinion as to the quality of the samples taken can be presented. No other procedures of quality control were employed.Disclosures

~~Interpretation~~No disclosure ~~and Conclusions~~required.

~~The~~Item 5 ~~locale~~- ofOther ~~the Bontoc Claim is underlain by the units of the Precambrian rocks that are found at those mineral occurrence sites.~~Information

~~These~~No disclosure ~~rocks consisting of cherts and argillites (sediments) and andesitic to basaltic volcanic have been intruded by granodiorite~~required. Structures and mineralization probably related to this intrusion are found throughout the region and occur on the claim. They are associated with all the major mineral occurrences and deposits in the area.

Mineralization found on the claim is consistent with that found associated with zones of extensive mineralization. Past work however has been limited and sporadic and has not tested the potential of the property.14

~~Potential~~Item 6 ~~for~~- ~~significant amounts of mineralization to be found exists on the property and it merits intensive exploration.~~Exhibits

16Index to Exhibits

Recommendations

Exhibit No.		Description

31.1*		Certification of Principal Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934.
31.2*		Certification of Principal Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934.
32.1*		Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*		Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS**		XBRL Instance Document.
101.SCH**		XBRL Taxonomy Extension Schema Document.
101.CAL**		XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF**		XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB**		XBRL Taxonomy Extension Label Linkbase Document.
101.PRE**		XBRL Taxonomy Extension Presentation Linkbase Document.

A* ~~two~~Filed ~~phased~~herewith ~~exploration~~** ~~program~~Furnished ~~to further delineate the mineralized system currently recognized on Bontoc Claim is recommended.~~herewith

The program would consist of air photo interpretation of the structures, geological mapping, both regionally and detailed on the area of the main showings, geophysical survey using both magnetic and electromagnetic instrumentation in detail over the area of the showings and in a regional reconnaissance survey and geochemical soil sample surveying regionally to identify other areas on the claim that are mineralized and in detail on the known areas of mineralization. The effort of this exploration work is to define and enable interpretation of a follow-up diamond drill program, so that the known mineralization and the whole property can be thoroughly evaluated with the most up to date exploration techniques.15

~~The proposed budget for the recommended work in US $43,964 or PHP 1,953,760 is as follows:~~SIGNATURES

Phase I	US Dollars		Philippine Peso
Geological Mapping	$	8,084		359,253
Geological Surveying		7,530		334,633
Total Phase I		15,614		693,886
Phase II
Geological surveying and surface sampling (including sample collection an assaying)		28,350		1,259,874
Total Phase II		28,350		1,259,874
Total of Phases I and II	$	43,964		1,953,760

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Competitive Factors

	Nexus BioPharma, Inc.

Date: October 24, 2016	By:	/s/ Warren Lau
		Warren Lau, Chief Executive Officer
		(Principal Executive Officer) and Chief Financial Officer (Principal Financial and Accounting Officer)

The gold mining industry is fragmented, that is there are many, many gold prospectors and producers, small and large. We do not compete with anyone. That is because there is no competition for the exploration or removal of minerals from the Bontoc Claim. Plata will either find gold on its claim or not. If we do not, we will cease or suspend operations. We are an infinitely small participant in the gold mining market. Readily available gold markets exist in Philippines and around the world for the sale of gold. Therefore, we believe we will be able to sell any gold that we are able to recover.16

Regulations

Our mineral exploration program is subject to the Philippine mineral requirements. The type of mining permit required in the Philippines by the Company is a MGB Form 50-1. During the exploration stage, the Company will engage the services of an exploration company who will be responsible for any fees and bonding requirements needed. The exact amount of the fees and bonding requirements will be known upon application for a mining permit. The Company, in conjunction with the exploration company, will make application to the Department of Environment and Natural Resources (DENR) Mines and Geosciences of the Philippines for its mining permit. The time frame for obtaining a mining permit is anywhere from 21 to 90 business days.

Subcontractors

We intend to use the services of subcontractors for manual labor exploration work on the Bontoc Claim. It is the directors' intention to engage the services of Geraldo Peralta, Professional Engineer, if he is available when needed, to supervise Phase I of our exploration program. If Mr. Peralta is not available the directors will attempt to locate another geologist to supervise the exploration program.

Employees and Employment Agreements

At present, we have no full-time employees. Our officers and directors do not have employment agreements with us. We presently do not have pension, health, annuity, insurance, stock options, profit sharing or similar benefit plans; however, we may adopt plans in the future. There are presently no personal benefits available to our officers and directors. Our officers and directors will handle our administrative duties. They engage a geologist to supervise the surveying and exploration work on the Bontoc claim.

Plan of Operation

We have not yet generated or realized any revenues from our business operations. In the future, unless we earn revenue or issue shares from our Treasury there might be the problem of Plata continuing as an on-going business. This is because we have not generated any revenues and no revenues are anticipated until we begin removing and selling minerals. There is no assurance we will ever reach this point. Accordingly, we must raise cash from sources other than the sale of minerals found on Bontoc Claim. Our only other source for cash at this time is investments by others. In the future, we must raise cash to implement our project and stay in business.

We will be conducting research in the form of exploration of our claim. Our exploration program is explained in as much detail as possible as in the prior pages. We intend complete Phase I in the late summer of 2016.

We are not going to buy or sell any plant or significant equipment during the next twelve months.

Our exploration target is to find an ore body containing gold or other salable minerals, if any. Our success depends upon finding mineralized material. This includes a determination by our directors and officers if the Bontoc Claim contains reserves. There is no assurance there is any mineralization on the Bontoc Claim. Mineralized material is a mineralized body, which has been delineated by appropriate spaced drilling or underground sampling to support sufficient tonnage and average grade of metals to justify removal. If we do not find mineralized material or we cannot remove mineralized material, either because we do not have the money to do it or because it is not economically feasible to do it, we will cease operations and our shareholders will lose their investment in Plata.

In addition, we may not have enough money to complete our entire exploration program as set forth by Geraldo Peralta on the Bontoc claim. We will have to raise additional funds to complete Phase II of our exploration program and there is no certainty that we will be able to do so when the time occurs. At the present time, we have not made any plans to raise additional money. If we need additional money and cannot raise it, we will have to suspend or cease operations.

We must conduct exploration to determine what amount of minerals, if any, exist on the Bontoc Claim and if any minerals which are found can be economically extracted and profitably processed.

Our claim is undeveloped raw land. Exploration and surveying has not been initiated and will not be initiated until Phase I is started and completed. To our knowledge and that of Geraldo Peralta, as set forth in his report, the Bontoc Claim has never been mined and there are no records of such with the Department of Mines for the Republic of the Philippines.

Before minerals retrieval can begin, we must explore for and find mineralized material. After that has occurred we have to determine if it is economically feasible to remove the mineralized material. Economically feasible means that the costs associated with the removal of the mineralized material will not exceed the price at which we can sell the mineralized material. We cannot predict what that will be until we find mineralized material.

We do not know if we will find mineralized material. We believe that activities occurring on adjoining properties are not material to our activities. The reason is that whatever is located on adjoining property may or may not be located on our claim.

We do not claim to have any minerals or reserves whatsoever at this time on any of the Bontoc Claim.

We intend to complete Phase I of our exploration program during the late summer of 2016 which will consist of geological mapping at a cost of $8,084 and geological surveying at a cost of $7,530. Our total cost for Phase I will be $15,614. The entire program, being both Phases I and II will consist of air photo interpretation of the structures, geological mapping, both regionally and detailed on the area of the main showings, geological survey using both magnetic and electromagnetic instrumentation in detail over the area of the showing and in a regional reconnaissance survey and geochemical soil sample surveying regionally to identify other areas on our claim that are mineralized and in detail on the known areas of mineralization. The effort of our exploration work is to define and enable interpretation of a follow-up diamond drill program, so that the known mineralization and the whole property can be thoroughly evaluated with the most up to date exploration techniques.

We estimate it will take up to 5 to 7 days to complete Phase I of our exploration program. The initial work on the Bontoc has commenced and has been detailed above. The completion is expected to occur during this summer.

There is no historical financial information about us upon which to base an evaluation of our performance. We have not generated any revenues from operations. We cannot guarantee we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources, possible delays in the exploration of the Bontoc claim, and possible cost overruns due to price and cost increases in services. To become profitable and competitive, we will conduct the research and exploration of the Bontoc claim before we start production of any minerals we may find. In the future we will have to seek equity funding to give us sufficient working capital to meet our ongoing obligations and continue our exploration activities on the Bontoc claim. We have no assurance that future financing will be available to us on acceptable terms. If financing is not available on satisfactory terms, we may be unable to continue, develop or expand our operations. Equity financing could result in an additional dilution to existing shareholders.

Trends

Management is unaware of any trends either currently or in the past which will have an impact on our operations.

Critical Accounting Policies and Estimates

In presenting our financial statements in conformity with U.S. generally accepting accounting principles, or GAAP, we are required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, costs and expenses and related disclosures.

Some of the estimates and assumptions we are required to make relate to matters that are inherently uncertain as they pertain to future events. We base these estimates and assumptions on historical experience or on various other factors that we believe to be reasonable and appropriate under the circumstances. On an ongoing basis, we reconsider and evaluate our estimates and assumptions. Actual results may differ significantly from these estimates.

We believe that the critical accounting policies listed below involve our more significant judgments, assumptions and estimates and, therefore, could have the greatest potential impact on our financial statements. In addition, we believe that a discussion of these policies is necessary to understand and evaluate the financial statements contained in this Form 10-Q.

Estimates and Assumptions

Management uses estimates and assumptions in preparing financial statements in accordance with general accepted accounting principles. Those estimates and assumptions affect the reported amounts of the assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were assumed in preparing these financial statements.

Mineral claim acquisition and exploration costs

The cost of acquiring mineral properties or claims is initially capitalized and then tested for recoverability whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. Mineral exploration costs are expensed as incurred.

Income Taxes

Recent Accounting Pronouncements

The Company does not expect the adoption of any other recent accounting pronouncements to have a material impact on its financial statements.

Public Market for Common Stock

Our shares are currently quoted on the OTC Bulletin Board ("OTCBB"). In order to remain on the OTCBB we must adhere to the rules and regulations of the OTCBB and the SEC.

The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the FINRA system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or quotation system. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock, to deliver a standardized risk disclosure document prepared by the SEC, that: (a) contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading; (b) contains a description of the broker's or dealer's duties to the customer and of the rights and remedies available to the customer with respect to a violation to such duties or other requirements of Securities laws; (c) contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price; (d) contains a toll-free telephone number for inquiries on disciplinary actions; (e) defines significant terms in the disclosure document or in the conduct of trading in penny stocks; and (f) contains such other information and is in such form, including language, type, size and format, as the SEC shall require by rule or regulation.

The broker-dealer also must provide, prior to effecting any transaction in a penny stock, the customer with: (a) bid and offer quotations for the penny stock; (b) the compensation of the broker-dealer and its salesperson in the transaction; (c) the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and (d) monthly account statements showing the market value of each penny stock held in the customer's account. In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from those rules; the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written acknowledgment of the receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a suitably written statement.

These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our stock if it becomes subject to these penny stock rules. Therefore, if our common stock becomes subject to the penny stock rules, stockholders may have difficulty selling those securities.

Rule 144 Shares

In general, under Rule 144, a person who is not one of our affiliates and who is not deemed to have been one of our affiliates at any time during the three months preceding a sale and who has beneficially owned shares of our common stock for at least six months would be entitled to sell them without restriction, subject to the continued availability of current public information about us (which current public information requirement is eliminated after a one-year holding period).

A person who is an affiliate and who has beneficially owned shares of a company's common stock for at least six months, subject to the continued availability of current public information about us, is entitled to sell within any three month period a number of shares that does not exceed the greater of:

1.	One percent of the number of shares of the company's common stock then outstanding; or
2.	The average weekly trading volume of the company's common stock during the four calendar weeks preceding the filing of a notice on form 144 with respect to the sale.

Rule 144 is not available for either a reporting or non-reporting shell company, as defined under Rule 405 of the Securities Act, unless the company:

· has ceased to be a shell company; · is subject to the Exchange Act reporting obligations; · has filed all required Exchange Act reports during the preceding twelve months; and · at least one year has elapsed from the time the company filed with the SEC, current Form 10 type information reflecting its status as an entity that is not a shell company.

Registration Rights

We have not granted registration rights to any person.

Dividends

There are no restrictions in our Articles of Incorporation or Bylaws that would prevent us from declaring dividends. The Nevada Revised Statutes, however, do prohibit us from declaring dividends where, after giving effect to the distribution of the dividend:

1. We would not be able to pay our debts as they become due in the usual course of business; or2. Our total assets would be less than the sum of our total liabilities plus the amount that would be needed to satisfy the rights of stockholders who have preferential rights superior to those receiving the distribution.

We have not declared any dividends and we do not plan to declare any dividends in the foreseeable future.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

The Company is a smaller reporting Company as defined by Rule 12b-2 of the Securities Act of 1934 and are not required to provide the information under this item.

ITEM 4. CONTROLS AND PROCEDURES.

Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Accounting Officer, we have evaluated the effectiveness of our disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of March 31, 2016 (the "Evaluation Date"). Based on that evaluation, the Chief Executive Officer and Chief Accounting Officer have concluded that these disclosure controls and procedures were not effective as of the Evaluation Date as a result of the material weaknesses in internal control over financial reporting.

Disclosure controls and procedures are those controls and procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Accounting Officer, to allow timely decisions regarding required disclosure.

Notwithstanding the assessment that our internal control over financial reporting was not effective and that there were material weaknesses as noted below, we believe that our financial statements contained in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 fairly present our financial condition, results of operations and cash flows in all material respects

The matters involving internal controls and procedures that the Company's management considered to be material weaknesses under the standards of the Public Company Accounting Oversight Board were: (1) lack of a functioning audit committee due to the lack of a majority of independent members and a lack of a majority of outside directors on our board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; (2) inadequate segregation of duties consistent with control objectives; and (3) ineffective controls over period end financial disclosure and reporting processes. The aforementioned material weaknesses were identified by our President and principle accounting officer in connection with the review of our financial statements as of March 31, 2016.

Management believes that the material weaknesses set forth in items (2) and (3) above did not have an effect on our financial results. However, management believes that the lack of a functioning audit committee and lack of a majority of outside directors on our board of directors, results in ineffective oversight in the establishment and monitoring of required internal controls and procedures which could result in a material misstatement in our financial statements in future periods.

Changes in Internal Controls

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

There are no legal proceedings to which Plata Resources is a party, or to which the Bontoc Claim is subject, nor to the best of management's knowledge are any material legal proceedings contemplated.

Item 1A. Risk Factors.

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Act of 1934 and are not required to provide the information under this item.

Item 2. Unregistered Sale of Equity Shares and Use of Proceeds.

Not Applicable

Item 3. Defaults Upon Senior Securities.

None

Item 4. Mine Safety Disclosure.

Not Applicable

Item 5. Other Information.

None

ITEM 6. EXHIBITS

(a) (3) Exhibits

The following exhibits are included as part of this report by reference:

3(i)		Articles of Incorporation (incorporated by reference from Plata Resources, Inc Registration Statement on Form SB-2 filed on February 1, 2008, Registration No.333-148984)
3(ii)		By-laws (incorporated by reference from Plata Resources, Inc. Registration Statement on Form SB-2 filed on February 1, 2008, Registration No. 333-148984)
31.1		Certification of Chief Executive Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (*)
31.2		Certification of Chief Financial Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (*)
32.1		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (*)
32.2		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of Sarbanes-Oxley Act of 2002 (*)
101.INS		XBRL Instance Document (*)
101.SCH		XBRL Taxonomy Extension Schema Document (*)
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document (*)
101.LAB		XBRL Taxonomy Extension Labels Linkbase Document (*)
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document (*)
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document (*)

__________

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	PLATA RESOURCES, INC.(Registrant)
Date: May 6, 2016	By:	/s/ "Dexter R. Caliso"
		Dexter R. Caliso
		Chief Executive Officer, President and Director
Date: May 6, 2016	By:	/s/ "Presentacion A. Coranes"
		Presentacion A. Coranes
		Chief Financial Officer, Chief Accounting
		Officer, Secretary and Director

Filing Compare · NEXUS BIOPHARMA INC